Drug intelligence / Profile preview

COLIRIOBCN070660

Development stage: Phase 3
Administration: Ophthalmic

Overview

COLIRIOBCN070660 is an investigational ophthalmic drug candidate in development for the treatment of diabetic retinopathy. It is currently listed among promising pipeline therapies for this indication, but detailed information about its mechanism of action, molecular modality, or developer has not been publicly disclosed as of April 2024. The drug appears to be in clinical development and has not yet reached regulatory approval[6][7].

Beyond the preview

Go deeper on COLIRIOBCN070660.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COLIRIOBCN070660.